Section Arrow
Quote
AARD.NASDAQ
- Aardvark Therapeutics Inc
Quotes are at least 15-min delayed:2026/02/09 02:27 EST
Regular Hours
Last
 12.65
+1.36 (+12.05%)
Day High 
13.03 
Prev. Close
11.29 
1-M High
16.6 
Volume 
152.07K 
Bid
12.62
Ask
13.27
Day Low
11.51 
Open
11.61 
1-M Low
11.135 
Market Cap 
245.82M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.41 
20-SMA 14.26 
50-SMA 13.42 
52-W High 19.58 
52-W Low 4.88 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.53/-2.59
Enterprise Value
246.26M
Balance Sheet
Book Value Per Share
5.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc1.84-0.21-10.24%-- 
RXRXRecursion Pharmaceuticals3.98+0.42+11.80%-- 
FOLDAmicus Therapeutics14.3+0.02+0.14%-- 
ARWRArrowhead Pharmaceuticals64.52-0.12-0.19%-- 
ROIVRoivant Sciences Ltd25.82+4.68+22.14%1.95PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.